Andrea G Hohmann

List of Publications by Year
in descending order

43 papers	3,630 citations	201674 27 h-index	243625 44 g-index
46 all docs	46 docs citations	46 times ranked	3718 citing authors

#	Article	IF	Citations
1	A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. Pain, 2022, 163, 834-851.	4.2	17
2	A limited access oral oxycodone paradigm produces physical dependence and mesocorticolimbic region-dependent increases in DeltaFosB expression without preference. Neuropharmacology, 2022, 205, 108925.	4.1	7
3	Cannabinoid CB₂ Receptor Activation Attenuates Fentanyl-Induced Respiratory Depression. Cannabis and Cannabinoid Research, 2021, 6, 389-400.	2.9	5
4	International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain, 2021, 162, S117-S124.	4.2	33
5	Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain, 2021, 162, S5-S25.	4.2	92
6	Inhaled Cannabis Suppresses Chemotherapy-Induced Neuropathic Nociception by Decoupling the Raphe Nucleus: A Functional Imaging Study in Rats. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 479-489.	1.5	11
7	Cannabidiol has a unique effect on global brain activity: a pharmacological, functional MRI study in awake mice. Journal of Translational Medicine, 2021, 19, 220.	4.4	9
8	Fecal microbiota transplantation and antibiotic treatment attenuate naloxone-precipitated opioid withdrawal in morphine-dependent mice. Experimental Neurology, 2021, 343, 113787.	4.1	27
9	Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain. Pain, 2021, 162, S26-S44.	4.2	75
10	NAAA-regulated lipid signaling governs the transition from acute to chronic pain. Science Advances, 2021, 7, eabi8834.	10.3	15
11	Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. Science Translational Medicine, 2021, 13, eabh1314.	12.4	23
12	Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. Journal of Medicinal Chemistry, 2020, 63, 542-568.	6.4	40
13	Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. Frontiers in Molecular Neuroscience, 2020, 13, 54.	2.9	42
14	The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence. European Journal of Pharmacology, 2020, 886, 173544.	3.5	27
15	Voluntary exercise reduces both chemotherapy-induced neuropathic nociception and deficits in hippocampal cellular proliferation in a mouse model of paclitaxel-induced peripheral neuropathy. Neurobiology of Pain (Cambridge, Mass), 2019, 6, 100035.	2.5	22
16	Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro. Pharmacological Research, 2019, 142, 267-282.	7.1	22
17	Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal. Molecular Pharmacology, 2019, 95, 155-168.	2.3	42
18	Disruption of nNOSâ€“NOS1AP proteinâ€“protein interactions suppresses neuropathic pain in mice. Pain, 2018, 159, 849-863.	4.2	17

#	Article	IF	Citations
19	Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. Biological Psychiatry, 2018, 84, 722-733.	1.3	101
20	Slowly Signaling G Proteinâ€"Biased CB₂Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence. Molecular Pharmacology, 2018, 93, 49-62.	2.3	56
21	Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 551-563.	2.5	32
22	ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability. Molecular Pain, 2018, 14, 174480691880122.	2.1	13
23	Small molecule inhibitors of PSD95â€"nNOS proteinâ€"protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats. Neuroscience, 2017, 349, 303-317.	2.3	27
24	Inflammatory and Neuropathic Nociception is Preserved in GPR55 Knockout Mice. Scientific Reports, 2017, 7, 944.	3.3	32
25	The cannabinoid system and pain. Neuropharmacology, 2017, 124, 105-120.	4.1	200
26	Cannabinoid CB₂Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB₁Mechanism that is Independent of CB₂Receptors in Mice. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 296-305.	2.5	31
27	A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase. Molecular Pain, 2016, 12, 174480691664919.	2.1	46
28	Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems. Pharmacological Research, 2016, 114, 75-89.	7.1	16
29	Impact of Genetic Reduction of NMNAT2 on Chemotherapy-Induced Losses in Cell Viability In Vitro and Peripheral Neuropathy In Vivo. PLoS ONE, 2016, 11, e0147620.	2.5	21
30	CB₁ Knockout Mice Unveil Sustained CB₂-Mediated Antiallodynic Effects of the Mixed CB₁/CB₂ Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain. Molecular Pharmacology, 2015, 88, 64-74.	2.3	54
31	Small molecule inhibitors of PSD95-nNOS proteinâ€"protein interactions as novel analgesics. Neuropharmacology, 2015, 97, 464-475.	4.1	54
32	Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1â€"Dependent Withdrawal. Biological Psychiatry, 2015, 77, 475-487.	1.3	179
33	A Lipid Gate for the Peripheral Control of Pain. Journal of Neuroscience, 2014, 34, 15184-15191.	3.6	56
34	Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: Effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacological Research, 2013, 67, 94-109.	7.1	135
35	Activation of Type 5 Metabotropic Glutamate Receptors and Diacylglycerol Lipase-Â Initiates 2-Arachidonoylglycerol Formation and Endocannabinoid-Mediated Analgesia. Journal of Neuroscience, 2012, 32, 9457-9468.	3.6	78
36	The endocannabinoid system and cancer: therapeutic implication. British Journal of Pharmacology, 2011, 163, 1447-1463.	5.4	168

#	Article	IF	Citations
37	Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: Antinociception without central nervous system side-effects. Pharmacology Biochemistry and Behavior, 2011, 98, 493-502.	2.9	55
38	Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nature Neuroscience, 2010, 13, 1265-1270.	14.8	289
39	Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacological Research, 2010, 62, 249-258.	7.1	45
40	Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside. Neurotherapeutics, 2009, 6, 713-737.	4.4	267
41	The Endocannabinoid System and Pain. CNS and Neurological Disorders - Drug Targets, 2009, 8, 403-421.	1.4	368
42	An endocannabinoid mechanism for stress-induced analgesia. Nature, 2005, 435, 1108-1112.	27.8	655
43	Neonatal Chronic Hind Paw Inflammation Alters Sensitization to Intradermal Capsaicin in Adult Rats: A Behavioral and Immunocytochemical Study. Journal of Pain, 2005, 6, 798-808.	1.4	45